易明医药(002826) - 2020 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2020 was ¥96,087,140.09, representing a decrease of 9.30% compared to ¥105,939,655.33 in the same period last year[9] - Net profit attributable to shareholders was ¥5,968,919.24, down 9.11% from ¥6,567,136.39 year-on-year[9] - The net profit after deducting non-recurring gains and losses was -¥1,393,743.13, a decline of 124.76% compared to ¥5,628,563.52 in the previous year[9] - Operating profit for Q1 2020 was -6,149,867.27 CNY, down from 4,073,890.01 CNY in Q1 2019, indicating a negative shift in operational performance[48] - The company reported a total comprehensive income of -2,553,737.01 CNY for Q1 2020, compared to 3,535,253.88 CNY in the same period last year, highlighting overall financial challenges[48] Cash Flow - The net cash flow from operating activities was -¥13,919,475.18, worsening by 91.57% from -¥7,265,933.10 in the same period last year[9] - Operating cash flow decreased by 91.57% to -¥13.92 million, impacted by the delay in receiving government funds[17] - The company experienced a net cash outflow from operating activities of -13,919,475.18 CNY, worsening from -7,265,933.10 CNY in the previous year[52] - Cash inflow from financing activities totaled 70,000,000.00 CNY, while cash outflow was 70,609,000.00 CNY, resulting in a net cash flow of -70,609,000.00 CNY[56] - The net increase in cash and cash equivalents was -74,291,942.57 CNY, with a closing balance of 23,235,731.50 CNY[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥769,755,220.24, a decrease of 7.86% from ¥835,405,794.28 at the end of the previous year[9] - The company's total assets decreased to CNY 656,935,371.77 from CNY 714,785,218.59, representing a reduction of 8.1%[41] - The total liabilities decreased from CNY 183,236,800.46 to CNY 110,584,788.55, a reduction of approximately 39.5%[35] - The company's current assets decreased to CNY 328,668,432.07 from CNY 400,567,707.61, representing a reduction of about 18%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,569[13] - The largest shareholder, Gao Fan, holds 26.26% of the shares, amounting to 50,744,682 shares[13] Government Support - The company received government subsidies totaling ¥4,584,750.01, primarily related to business support and clinical approvals[10] - The company received a total of ¥150 million in subsidies for clinical approvals and market compensation during the reporting period[18] - Other income surged by 4815.94% to ¥3.08 million, mainly from government subsidies[17] Expenses - Total operating costs for Q1 2020 were CNY 95,674,672.74, down from CNY 101,154,273.21, reflecting a reduction of 5.0%[42] - Research and development expenses increased to CNY 600,076.62 from CNY 514,162.37, showing a growth of 16.7%[42] - Sales expenses for Q1 2020 were 16,239,071.24 CNY, down from 18,409,703.51 CNY in Q1 2019, suggesting cost control measures[48] Other Information - The company reported no derivative investments during the reporting period[26] - There were no instances of non-compliance with external guarantees during the reporting period[27] - The company did not engage in any non-operating fund occupation by controlling shareholders or related parties[28] - The company did not conduct any research, communication, or interview activities during the reporting period[29] - The first quarter report was not audited[58]